Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board
Amount Raised
$70 Million
Round Type
series c
Description
Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, today announced the company had raised $70 million in new equity funding. Led with the increased funding by the current investor, Mattias Westman, founding partner of Prosperity Capital Management, the oversubscribed Series C round includes several existing investors and multiple new investors: Pathology Asia Holdings Pte Ltd (Pathology Asia), the largest independent medical diagnostics group in Southeast Asia, as well as a venture fund based in San Francisco, CA, and a large, diversified asset manager on the west coast, among others. VAHOCA Pte Ltd acted as a financial advisor to Bluestar Genomics.